United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. Our lead product, Remodulin, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as Hepatitis C. For more information about United Therapeutics' pipeline, click here

To receive press releases, quarterly and annual SEC filings, please click here.

Current Press Releases

Jun 9, 2009
Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

May 26, 2009
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension

more »

Events

Aug 5, 2009
BMO Capital Markets 9th Annual Focus On Healthcare Conference, New York: August 5, 2009

Sep 9, 2009
Rodman & Renshaw 11th Annual Healthcare Conference, New York: September 9-11, 2009

Sep 15, 2009
Morgan Stanley Global Healthcare Unplugged Conference, New York: September 14-15, 2009

more »